Pharma BD Deal Intelligence

Pfizer Inc. / Chai Discovery, Inc.

2026 · Licensing/Option · Complete

Chai Discovery entered a license agreement with Pfizer allowing Pfizer to deploy Chai's AI platform inside its drug discovery engine. Pfizer gains early access to Chai-3, Chai Discovery's most advanced model, together with a custom model that leverages Pfizer's proprietary data and is tailored to Pfizer's workflows. Chai-3 is reported to roughly double the antibody design success rate of its predecessor and to extend to multispecific design and broader target generalization. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Pfizer Inc. deals